PANCRAZZI, ALESSANDRO
PANCRAZZI, ALESSANDRO
Medicina Sperimentale e Clinica
A pathobiological pathway linking thrombopoietin, GATA1 and TGFbeta1 in the development of myelofibrosis
2005 VANNUCCHI AM.; BIANCHI L.; F. PAOLETTI; PANCRAZZI A.; TORRE E.; NISHIKAWA M.; ZINGARIELLO M.; DI BALDASSARRE A.; RANA RA.; LORENZINI R.; ALFANI E.; MIGLIACCIO G.; MIGLIACCIO AR.
A QUANTITATIVE ASSAY FOR JAK2V617F MUTATION IN MYELOPROLIFERATIVE DISORDERS BY ARMS-PCR AND CAPILLARY ELECTROPHORESIS
2006 A. VANNUCCHI; A. PANCRAZZI; C. BOGANI; E. ANTONIOLI; P. GUGLIELMELLI
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.
2008 Alessandro Pancrazzi; Paola Guglielmelli; Vanessa Ponziani; Gaetano Bergamaschi; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis.
2005 A. M. Vannucchi;A. Pancrazzi;P. Guglielmelli;S. D. Lollo;C. Bogani;G. Baroni;L. Bianchi;A. R. Migliaccio;A. Bosi;F. Paoletti
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms.
2013 Rumi E;Pietra D;Guglielmelli P;Bordoni R;Casetti I;Milanesi C;Sant'Antonio E;Ferretti V;Pancrazzi A;Rotunno G;Severgnini M;Pietrelli A;Astori C;Fugazza E;Pascutto C;Boveri E;Passamonti F;De Bellis G;Vannucchi A;Cazzola M.
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.
2007 Paola Guglielmelli; Alessandro Pancrazzi; Gaetano Bergamaschi; Vittorio Rosti; Laura Villani; Elisabetta Antonioli; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi;
Analisi mutazionale delle malattie mieloproliferative croniche
2007 Alessandro M. Vannucchi; Alessandro Pancrazzi; paola guglielmelli; Vanessa Ponziani
ANALISI MUTAZIONALI DELLE MALATTIE MIELOPROLIFERTAIVE CRONICHE
2008 PANCRAZZI A; AM VANNUCCHI; V. PONZIANI; P. GUGLIELMELLI
ANALYSIS OF ASXL1 MUTATIONS IN 215 PATIENTS WITH MYELOFIBROSIS : IMPACT ON DISEASE PHENOTYPE AND PROGNOSIS
2011 Biamonte F;Guglielmelli P;Fanelli T;Pancrazzi A;Villani L;Bosi A;Barosi G;Vannucchi AM
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis.
2007 Costanza Bogani; Paola Guglielmelli; Elisabetta Antonioli; Alessandro Pancrazzi; Alberto Bosi; Alessandro Maria Vannucchi
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.
2014 Tefferi A;Guglielmelli P;Lasho TL;Rotunno G;Finke C;Mannarelli C;Belachew AA;Pancrazzi A;Wassie EA;Ketterling RP;Hanson CA;Pardanani A;Vannucchi AM
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group
2014 Guglielmelli, P; Rotunno, G; Brogi, G; Pacilli, A; Bogani, C; Mannarelli, C; Pancrazzi, A; Fjerza, R; Pieri, L; Rumi, E; Pietra, D; Salmoiraghi, S; Provenzano, A; Giunti, L; Giglio, S; Maffioli, M; Bosi, A; Rambaldi, A; Barbui, T; Passamonti, F; Cazzola, M; Vannucchi, Am
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.
2008 Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Pancrazzi; Vittoria Guerini; Giovanni Barosi; Marco Ruggeri; Giorgina Specchia; Francesco Lo-Coco; Federica Delaini; Laura Villani; Silvia Finotto; Emanuele Ammatuna; Renato Alterini; Valentina Carrai; Gloria Capaccioli; Simonetta Di Lollo; Vincenzo Liso; Alessandro Rambaldi; Alberto Bosi; Tiziano Barbui
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.
2005 Antonioli E; Guglielmelli P; Pancrazzi A; Bogani C; Verrucci M; Ponziani V; Longo G; Bosi A; Vannucchi AM.
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib
2017 Pacilli, Annalisa; Fanelli, Tiziana; Mannarelli, Carmela; Rotunno, Giada; Pancrazzi, Alessandro; Vannucchi, Alessandro Maria; Guglielmelli, Paola
CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin.
2010 Verrucci M; Pancrazzi A; Aracil M; Martelli F; Guglielmelli P; Zingariello M; Ghinassi B; D'Amore E; Jimeno J; Vannucchi AM; Migliaccio AR.
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group
2016 Rotunno, Giada; Pacilli, Annalisa; Artusi, Valentina; Rumi, Elisa; Maffioli, Margherita; Delaini, Federica; Brogi, Giada; Fanelli, Tiziana; Pancrazzi, Alessandro; Pietra, Daniela; Bernardis, Isabella; Belotti, Clara; Pieri, Lisa; Sant'Antonio, Emanuela; Salmoiraghi, Silvia; Cilloni, Daniela; Rambaldi, Alessandro; Passamonti, Francesco; Barbui, Tiziano; Manfredini, Rossella; Cazzola, Mario; Tagliafico, Enrico; Vannucchi, Alessandro M; Guglielmelli, Paola
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.
2013 Jovanovic JV;Ivey A;Vannucchi AM;Lippert E;Oppliger Leibundgut E;Cassinat B;Pallisgaard N;Maroc N;Hermouet S;Nickless G;Guglielmelli P;van der Reijden BA;Jansen JH;Alpermann T;Schnittger S;Bench A;Tobal K;Wilkins B;Cuthill K;McLornan D;Yeoman K;Akiki S;Bryon J;Jeffries S;Jones A;Percy MJ;Schwemmers S;Gruender A;Kelley TW;Reading S;Pancrazzi A;McMullin MF;Pahl HL;Cross NC;Harrison CN;Prchal JT;Chomienne C;Kiladjian JJ;Barbui T;Grimwade D
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis.
2010 P. Guglielmelli;F. Biamonte;A. Spolverini;L. Pieri;A. Isgrò;E. Antonioli;A. Pancrazzi;A. Bosi;G. Barosi;A.M. Vannucchi
GROWTH INHIBITION AND DIFFERENTIATION OF HUMAN BREAST CANCER CELLS BY THE PAFR ANTAGONIST WEB-2086
2006 CELLAI C; LAURENZANA A; VANNUCCHI AM; CAPORALE R; PAGLIERANI M; DI LOLLO S; PANCRAZZI A; PAOLETTI F
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A pathobiological pathway linking thrombopoietin, GATA1 and TGFbeta1 in the development of myelofibrosis | 2005 | VANNUCCHI AM.; BIANCHI L.; F. PAOLETTI; PANCRAZZI A.; TORRE E.; NISHIKAWA M.; ZINGARIELLO M.; DI BALDASSARRE A.; RANA RA.; LORENZINI R.; ALFANI E.; MIGLIACCIO G.; MIGLIACCIO AR. | |
| A QUANTITATIVE ASSAY FOR JAK2V617F MUTATION IN MYELOPROLIFERATIVE DISORDERS BY ARMS-PCR AND CAPILLARY ELECTROPHORESIS | 2006 | A. VANNUCCHI; A. PANCRAZZI; C. BOGANI; E. ANTONIOLI; P. GUGLIELMELLI | |
| A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. | 2008 | Alessandro Pancrazzi; Paola Guglielmelli; Vanessa Ponziani; Gaetano Bergamaschi; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi | |
| Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. | 2005 | A. M. Vannucchi;A. Pancrazzi;P. Guglielmelli;S. D. Lollo;C. Bogani;G. Baroni;L. Bianchi;A. R. Migliaccio;A. Bosi;F. Paoletti | |
| Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. | 2013 | Rumi E;Pietra D;Guglielmelli P;Bordoni R;Casetti I;Milanesi C;Sant'Antonio E;Ferretti V;Pancrazzi A;Rotunno G;Severgnini M;Pietrelli A;Astori C;Fugazza E;Pascutto C;Boveri E;Passamonti F;De Bellis G;Vannucchi A;Cazzola M. | |
| Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. | 2007 | Paola Guglielmelli; Alessandro Pancrazzi; Gaetano Bergamaschi; Vittorio Rosti; Laura Villani; Elisabetta Antonioli; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi; | |
| Analisi mutazionale delle malattie mieloproliferative croniche | 2007 | Alessandro M. Vannucchi; Alessandro Pancrazzi; paola guglielmelli; Vanessa Ponziani | |
| ANALISI MUTAZIONALI DELLE MALATTIE MIELOPROLIFERTAIVE CRONICHE | 2008 | PANCRAZZI A; AM VANNUCCHI; V. PONZIANI; P. GUGLIELMELLI | |
| ANALYSIS OF ASXL1 MUTATIONS IN 215 PATIENTS WITH MYELOFIBROSIS : IMPACT ON DISEASE PHENOTYPE AND PROGNOSIS | 2011 | Biamonte F;Guglielmelli P;Fanelli T;Pancrazzi A;Villani L;Bosi A;Barosi G;Vannucchi AM | |
| B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. | 2007 | Costanza Bogani; Paola Guglielmelli; Elisabetta Antonioli; Alessandro Pancrazzi; Alberto Bosi; Alessandro Maria Vannucchi | |
| CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. | 2014 | Tefferi A;Guglielmelli P;Lasho TL;Rotunno G;Finke C;Mannarelli C;Belachew AA;Pancrazzi A;Wassie EA;Ketterling RP;Hanson CA;Pardanani A;Vannucchi AM | |
| Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group | 2014 | Guglielmelli, P; Rotunno, G; Brogi, G; Pacilli, A; Bogani, C; Mannarelli, C; Pancrazzi, A; Fjerza, R; Pieri, L; Rumi, E; Pietra, D; Salmoiraghi, S; Provenzano, A; Giunti, L; Giglio, S; Maffioli, M; Bosi, A; Rambaldi, A; Barbui, T; Passamonti, F; Cazzola, M; Vannucchi, Am | |
| Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. | 2008 | Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Pancrazzi; Vittoria Guerini; Giovanni Barosi; Marco Ruggeri; Giorgina Specchia; Francesco Lo-Coco; Federica Delaini; Laura Villani; Silvia Finotto; Emanuele Ammatuna; Renato Alterini; Valentina Carrai; Gloria Capaccioli; Simonetta Di Lollo; Vincenzo Liso; Alessandro Rambaldi; Alberto Bosi; Tiziano Barbui | |
| Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. | 2005 | Antonioli E; Guglielmelli P; Pancrazzi A; Bogani C; Verrucci M; Ponziani V; Longo G; Bosi A; Vannucchi AM. | |
| Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib | 2017 | Pacilli, Annalisa; Fanelli, Tiziana; Mannarelli, Carmela; Rotunno, Giada; Pancrazzi, Alessandro; Vannucchi, Alessandro Maria; Guglielmelli, Paola | |
| CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin. | 2010 | Verrucci M; Pancrazzi A; Aracil M; Martelli F; Guglielmelli P; Zingariello M; Ghinassi B; D'Amore E; Jimeno J; Vannucchi AM; Migliaccio AR. | |
| Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group | 2016 | Rotunno, Giada; Pacilli, Annalisa; Artusi, Valentina; Rumi, Elisa; Maffioli, Margherita; Delaini, Federica; Brogi, Giada; Fanelli, Tiziana; Pancrazzi, Alessandro; Pietra, Daniela; Bernardis, Isabella; Belotti, Clara; Pieri, Lisa; Sant'Antonio, Emanuela; Salmoiraghi, Silvia; Cilloni, Daniela; Rambaldi, Alessandro; Passamonti, Francesco; Barbui, Tiziano; Manfredini, Rossella; Cazzola, Mario; Tagliafico, Enrico; Vannucchi, Alessandro M; Guglielmelli, Paola | |
| Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. | 2013 | Jovanovic JV;Ivey A;Vannucchi AM;Lippert E;Oppliger Leibundgut E;Cassinat B;Pallisgaard N;Maroc N;Hermouet S;Nickless G;Guglielmelli P;van der Reijden BA;Jansen JH;Alpermann T;Schnittger S;Bench A;Tobal K;Wilkins B;Cuthill K;McLornan D;Yeoman K;Akiki S;Bryon J;Jeffries S;Jones A;Percy MJ;Schwemmers S;Gruender A;Kelley TW;Reading S;Pancrazzi A;McMullin MF;Pahl HL;Cross NC;Harrison CN;Prchal JT;Chomienne C;Kiladjian JJ;Barbui T;Grimwade D | |
| Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. | 2010 | P. Guglielmelli;F. Biamonte;A. Spolverini;L. Pieri;A. Isgrò;E. Antonioli;A. Pancrazzi;A. Bosi;G. Barosi;A.M. Vannucchi | |
| GROWTH INHIBITION AND DIFFERENTIATION OF HUMAN BREAST CANCER CELLS BY THE PAFR ANTAGONIST WEB-2086 | 2006 | CELLAI C; LAURENZANA A; VANNUCCHI AM; CAPORALE R; PAGLIERANI M; DI LOLLO S; PANCRAZZI A; PAOLETTI F |